Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
0.6849
-0.0751 (-9.88%)
At close: Jul 13, 2026, 4:00 PM EDT
0.6936
+0.0087 (1.27%)
After-hours: Jul 13, 2026, 7:36 PM EDT
Traws Pharma Revenue
Traws Pharma had revenue of $2.73M in the twelve months ending March 31, 2026, up 1,103.96% year-over-year. In the year 2025, Traws Pharma had annual revenue of $2.79M with 1,134.51% growth.
Revenue (ttm)
$2.73M
Revenue Growth
+1,103.96%
P/S Ratio
3.88
Revenue / Employee
$390,429
Employees
7
Market Cap
10.38M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.79M | 2.56M | 1,134.51% |
| Dec 31, 2024 | 226.00K | - | - |
| Dec 31, 2023 | 226.00K | - | - |
| Dec 31, 2022 | 226.00K | - | - |
| Dec 31, 2021 | 226.00K | -5.00K | -2.16% |
| Dec 31, 2020 | 231.00K | -1.95M | -89.42% |
| Dec 31, 2019 | 2.18M | 955.00K | 77.77% |
| Dec 31, 2018 | 1.23M | 441.00K | 56.04% |
| Dec 31, 2017 | 787.00K | -4.76M | -85.81% |
| Dec 31, 2016 | 5.55M | -5.91M | -51.59% |
| Dec 31, 2015 | 11.46M | 10.66M | 1,332.00% |
| Dec 31, 2014 | 800.00K | -3.95M | -83.17% |
| Dec 31, 2013 | 4.75M | -41.44M | -89.71% |
| Dec 31, 2012 | 46.19M | 44.70M | 3,006.25% |
| Dec 31, 2011 | 1.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| OSR Health | 2.63M |
| Vistagen Therapeutics | 1.27M |
| CytoMed Therapeutics | 669.28K |
| Exicure | 500.00K |
| Kiora Pharmaceuticals | 20.00K |
TRAW News
- 5 days ago - Traws Pharma Transcript: AGM 2026 - Transcripts
- 12 days ago - Traws Pharma files $139.19M mixed securities shelf - TheFly
- 12 days ago - Traws Pharma Registration statement: Registration filing - Filings
- 21 days ago - Traws Pharma provides update on tivoxavir marboxil program - TheFly
- 21 days ago - Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program - GlobeNewsWire
- 25 days ago - Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 4 weeks ago - Traws Pharma downgraded to Neutral from Buy at Ladenburg - TheFly
- 4 weeks ago - Traws Pharma influenza challenge study deferred following MHRA review - TheFly